35:I[703058,["/_next/static/immutable/chunks/355lxm8rh3fxr.js","/_next/static/immutable/chunks/0yecwcl2vsgzm.js","/_next/static/immutable/chunks/33s6yl_7t575t.js","/_next/static/immutable/chunks/2sgwc-d-l730j.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/34zte87e1oxbr.js","/_next/static/immutable/chunks/3o8_7x7kr1gqd.js","/_next/static/immutable/chunks/3gndzt6n9hhhz.js","/_next/static/immutable/chunks/368brjxhfaune.js","/_next/static/immutable/chunks/2-7hs63mi7grl.js","/_next/static/immutable/chunks/1xa6orki-joi9.js","/_next/static/immutable/chunks/316o2u2mp21uq.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/0g9dls0-elfj5.js"],"PaperListPageClient"] 36:T995,Seizures are a known complication of cancer, but whether they may be the first sign of undiagnosed neurological and nonneurological cancer remains unclear. To examine neurological and nonneurological cancer risk in patients with first-time seizures vs the general population. This population-based cohort study was conducted using nationwide Danish medical registries from January 1996 through December 2022. Follow-up extended until cancer diagnosis (excluding nonmelanoma skin cancer), emigration, death, or December 31, 2022. Analyses were performed from January 2025 through December 2025. All persons aged 18 years or older with a first-time hospital diagnosis of seizure and no preceding cancer were included. First-time seizure diagnosis. The primary outcomes were absolute risks (ARs) of cancer and standardized incidence ratios (SIRs) relative to the general Danish population with 95% confidence intervals, which were computed for all cancers, neurological and nonneurological cancers, and site-specific cancer within 1 year, from 1 to less than 5 years, and from 5 to 20 years after the first seizure. Among 49 894 adults with first-time seizure (median [IQR] age at seizure diagnosis, 51.5 [35.6-67.8] years; 20 648 [41.4%] women), a total of 1172 neurological and 850 nonneurological cancers were observed within the first year of follow-up; 87 neurological and 1226 nonneurological cancers were observed during the period from 1 to less than 5 years; and 112 neurological and 2120 nonneurological cancers were observed during the period from 5 to 20 years. In these time periods, the ARs for any cancer were 4.1%, 3.5%, and 13.4%, with SIRs of 5.30 (95% CI, 5.07-5.54), 1.18 (95% CI, 1.12-1.25), and 1.34 (95% CI, 1.28-1.40). ARs for neurological cancers were 2.4%, 0.2%, and 0.7%, with SIRs of 76.1 (95% CI, 71.8-80.6), 1.85 (95% CI, 1.48-2.28), and 1.46 (95% CI, 1.20-1.75). ARs for nonneurological cancers were 1.7%, 3.3%, and 12.8%, with SIRs of 2.32 (95% CI, 2.17-2.48), 1.15 (95% CI, 1.09-1.22), and 1.33 (95% CI, 1.28-1.39). Per the results of this cohort study, first-time seizures were associated with clearly elevated short-term relative risk of cancer and slightly elevated long-term risk, indicating they may be an early clinical sign of both neurological and nonneurological occult cancers. These findings highlight the importance of considering broader diagnostic assessments after first-time seizures in select patients.37:Te68, Importance Seizures are a known complication of cancer, but whether they may be the first sign of undiagnosed neurological and nonneurological cancer remains unclear. Objective To examine neurological and nonneurological cancer risk in patients with first-time seizures vs the general population. Design, Setting, and Participants This population-based cohort study was conducted using nationwide Danish medical registries from January 1996 through December 2022. Follow-up extended until cancer diagnosis (excluding nonmelanoma skin cancer), emigration, death, or December 31, 2022. Analyses were performed from January 2025 through December 2025. All persons aged 18 years or older with a first-time hospital diagnosis of seizure and no preceding cancer were included. Exposure First-time seizure diagnosis. Main Outcomes and Measures The primary outcomes were absolute risks (ARs) of cancer and standardized incidence ratios (SIRs) relative to the general Danish population with 95% confidence intervals, which were computed for all cancers, neurological and nonneurological cancers, and site-specific cancer within 1 year, from 1 to less than 5 years, and from 5 to 20 years after the first seizure. Results Among 49 894 adults with first-time seizure (median [IQR] age at seizure diagnosis, 51.5 [35.6-67.8] years; 20 648 [41.4%] women), a total of 1172 neurological and 850 nonneurological cancers were observed within the first year of follow-up; 87 neurological and 1226 nonneurological cancers were observed during the period from 1 to less than 5 years; and 112 neurological and 2120 nonneurological cancers were observed during the period from 5 to 20 years. In these time periods, the ARs for any cancer were 4.1%, 3.5%, and 13.4%, with SIRs of 5.30 (95% CI, 5.07-5.54), 1.18 (95% CI, 1.12-1.25), and 1.34 (95% CI, 1.28-1.40). ARs for neurological cancers were 2.4%, 0.2%, and 0.7%, with SIRs of 76.1 (95% CI, 71.8-80.6), 1.85 (95% CI, 1.48-2.28), and 1.46 (95% CI, 1.20-1.75). ARs for nonneurological cancers were 1.7%, 3.3%, and 12.8%, with SIRs of 2.32 (95% CI, 2.17-2.48), 1.15 (95% CI, 1.09-1.22), and 1.33 (95% CI, 1.28-1.39). Conclusions and Relevance Per the results of this cohort study, first-time seizures were associated with clearly elevated short-term relative risk of cancer and slightly elevated long-term risk, indicating they may be an early clinical sign of both neurological and nonneurological occult cancers. These findings highlight the importance of considering broader diagnostic assessments after first-time seizures in select patients. 22:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Plasma Biomarkers for Neocortical Tau Burden\",\"description\":\"JAMA Neurology, Aug 2026 · 560 patients. “Full text was not accessible; summary is based solely on the abstract and results section provided.” Read the key result, limitations and practice takeaway.\",\"url\":\"https://www.reachrx.ai/hub/tag/warning/Full%20text%20was%20not%20accessible%3B%20summary%20is%20based%20solely%20on%20the%20abstract%20and%20results%20section%20provided.\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Study limitation\",\"item\":\"https://www.reachrx.ai/hub/tag/warning/Full%20text%20was%20not%20accessible%3B%20summary%20is%20based%20solely%20on%20the%20abstract%20and%20results%20section%20provided.\"}]}}"}}]],["$","$L35",null,{"title":"Plasma Biomarkers for Neocortical Tau Burden","description":"Study limitation reported by the research below: “Full text was not accessible; summary is based solely on the abstract and results section provided.”","papers":[{"doi":"10.1001/jamaneurol.2026.2650","pmid":"42573994","title":"Plasma Biomarkers for Neocortical Tau Burden","journal_title":"JAMA Neurology","journal_issn":"2168-6149","published_at":"2026-08-10T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13458947/","source_score":117,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-17T13:33:02.912Z","updated_at":"2026-08-17T13:33:02.912Z","tags":[{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"condition","value":"Alzheimer Disease","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"condition","value":"Neurofibrillary Tangle Pathology","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"generic","value":"phosphorylated tau-217","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"modality","value":"Plasma Biomarker Panel","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"sample_size","value":"n=560","value_numeric":560},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"study_design","value":"Multicenter Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"warning","value":"Full text was not accessible; summary is based solely on the abstract and results section provided.","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"warning","value":"Study included only amyloid-positive individuals; performance in amyloid-negative or unselected populations is unknown.","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"warning","value":"The 7 specific proteins in the panel are not named in the available text, limiting clinical implementation details.","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.2650","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the potential significance of a validated blood-based tau staging tool, but the study is observational and requires prospective clinical validation before practice change.","value_numeric":null}],"summaries":{"what_studied":"A 7-protein plasma panel (measured via Nucleic Linked Immuno-Sandwich Assay) was developed and validated across two independent cohorts (BioFINDER, n=431; TRIAD, n=129) to improve identification of advanced neocortical tau pathology (Braak stage V/VI by tau PET) in amyloid-positive individuals spanning cognitively unimpaired to dementia, using cross-sectional data collected 2017–2024.","key_result":"The 7-protein panel outperformed p-tau217 alone in identifying Braak V/VI tau PET uptake in both cohorts (AUC 0.92–0.94 vs. 0.86–0.88; DeLong P < .001), and reduced the intermediate-risk (indeterminate) classification rate by 14.7%–21.0% in the validation cohort.","limitations":"Cross-sectional design prevents causal or longitudinal conclusions. The full-text was not accessible for complete methodological review. The panel was derived and validated only in amyloid-positive individuals, limiting generalizability to unselected or amyloid-negative populations.","practice_takeaway":"A 7-protein plasma panel may offer a scalable blood-based alternative to tau PET for staging advanced tau pathology in amyloid-positive patients, which is relevant for anti-amyloid therapy selection and anti-tau trial enrollment. Clinicians should note this is still observational and not yet validated in routine care settings."}},{"doi":"10.1001/jamaneurol.2026.0894","pmid":"42043826","title":"Risk of Cancer in Patients With First-Time Seizure","journal_title":"JAMA Neurology","journal_issn":"2168-6149","published_at":"2026-04-27T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13122496/","source_score":54,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-30","doi":"10.1001/jamaneurol.2026.0894","days":"14","issn":"2168-6149","rank":"7","field":"Clinical Medicine","score":"54","category":"Clinical Neurology","categories":["Clinical Neurology"],"_categories":["Clinical Neurology"]},"pubmed":{"doi":"10.1001/jamaneurol.2026.0894","title":"Risk of Cancer in Patients With First-Time Seizure.","journal":"JAMA neurology","methods":"","results":"Among 49 894 adults with first-time seizure (median [IQR] age at seizure diagnosis, 51.5 [35.6-67.8] years; 20 648 [41.4%] women), a total of 1172 neurological and 850 nonneurological cancers were observed within the first year of follow-up; 87 neurological and 1226 nonneurological cancers were observed during the period from 1 to less than 5 years; and 112 neurological and 2120 nonneurological cancers were observed during the period from 5 to 20 years. In these time periods, the ARs for any cancer were 4.1%, 3.5%, and 13.4%, with SIRs of 5.30 (95% CI, 5.07-5.54), 1.18 (95% CI, 1.12-1.25), and 1.34 (95% CI, 1.28-1.40). ARs for neurological cancers were 2.4%, 0.2%, and 0.7%, with SIRs of 76.1 (95% CI, 71.8-80.6), 1.85 (95% CI, 1.48-2.28), and 1.46 (95% CI, 1.20-1.75). ARs for nonneurological cancers were 1.7%, 3.3%, and 12.8%, with SIRs of 2.32 (95% CI, 2.17-2.48), 1.15 (95% CI, 1.09-1.22), and 1.33 (95% CI, 1.28-1.39).","abstract":"$36","keywords":[],"pubmed_id":"42043826","conclusions":"","publication_date":"2026-04-27T00:00:00"},"crossref":{"DOI":"10.1001/jamaneurol.2026.0894","URL":"https://doi.org/10.1001/jamaneurol.2026.0894","ISSN":["2168-6149"],"link":[{"URL":"https://jamanetwork.com/journals/jamaneurology/articlepdf/2848080/jamaneurology_pedersen_2026_oi_260021_1776347144.0642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Risk of Cancer in Patients With First-Time Seizure"],"author":[{"given":"Andreas Lund","family":"Pedersen","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Dóra Körmendiné","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Cecilia Hvitfeldt","family":"Fuglsang","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Victor W.","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Epidemiology and Population Health and Department of Neurology and Neurological Sciences, Stanford University, Stanford, California"}]},{"given":"Sofie Kejlberg","family":"Al-Mashhadi","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Holly","family":"Elser","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"},{"name":"Hospital of the University of Pennsylvania, Philadelphia"},{"name":"Associate Editor, JAMA Neurology"}]},{"given":"Henrik Toft","family":"Sørensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark"}]}],"issued":{"date-parts":[[2026,4,27]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-04-27T15:30:50Z","timestamp":1777303850000,"date-parts":[[2026,4,27]]},"indexed":{"date-time":"2026-04-27T16:01:28Z","timestamp":1777305688195,"date-parts":[[2026,4,27]]},"subject":[],"abstract":"$37","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaneurology/fullarticle/2848080"}},"subtitle":[],"deposited":{"date-time":"2026-04-27T15:30:55Z","timestamp":1777303855000,"date-parts":[[2026,4,27]]},"issn-type":[{"type":"print","value":"2168-6149"}],"published":{"date-parts":[[2026,4,27]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1111/j.1528-1167.2008.01443.x","key":"noi260021r2","year":"2008","issue":"s1","author":"Hauser","volume":"49","first-page":"8","unstructured":null,"article-title":"First seizure definitions and worldwide incidence and mortality.","journal-title":"Epilepsia","doi-asserted-by":"publisher"},{"DOI":"10.1212/WNL.0000000000001487","key":"noi260021r4","year":"2015","issue":"16","author":"Krumholz","volume":"84","first-page":"1705","unstructured":null,"article-title":"Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.","journal-title":"Neurology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2007.11.008","key":"noi260021r5","year":"2008","issue":"4","author":"von Elm","volume":"61","first-page":"344","unstructured":null,"article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","journal-title":"J Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.2147/CLEP.S179083","key":"noi260021r6","year":"2019","issue":null,"author":"Schmidt","volume":"11","first-page":"563","unstructured":null,"article-title":"The Danish health care system and epidemiological research: from health care contacts to database records.","journal-title":"Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10654-014-9930-3","key":"noi260021r7","year":"2014","issue":"8","author":"Schmidt","volume":"29","first-page":"541","unstructured":null,"article-title":"The Danish Civil Registration System as a tool in epidemiology.","journal-title":"Eur J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1177/1403494810387965","key":"noi260021r8","year":"2011","issue":"7","author":"Pedersen","volume":"39","first-page":"22","unstructured":null,"article-title":"The Danish Civil Registration System.","journal-title":"Scand J Public Health","doi-asserted-by":"publisher"},{"DOI":"10.2147/CLEP.S91125","key":"noi260021r9","year":"2015","issue":null,"author":"Schmidt","volume":"7","first-page":"449","unstructured":null,"article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential.","journal-title":"Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1177/1403494810393562","key":"noi260021r10","year":"2011","issue":"7","author":"Gjerstorff","volume":"39","first-page":"42","unstructured":null,"article-title":"The Danish Cancer Registry.","journal-title":"Scand J Public Health","doi-asserted-by":"publisher"},{"DOI":"10.2147/CLEP.S32004","key":"noi260021r11","year":"2012","issue":"Suppl 2","author":"Nguyen-Nielsen","volume":"4","first-page":"17","unstructured":null,"article-title":"Completeness of prostate cancer staging in the Danish Cancer Registry, 2004-2009.","journal-title":"Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1212/WNL.0000000000004538","key":"noi260021r12","year":"2017","issue":"14","author":"Reznik","volume":"89","first-page":"1476","unstructured":null,"article-title":"Long-term risk of seizures in adult survivors of sepsis.","journal-title":"Neurology","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1473-3099(10)70222-X","key":"noi260021r13","year":"2010","issue":"12","author":"Granerod","volume":"10","first-page":"835","unstructured":null,"article-title":"Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study.","journal-title":"Lancet Infect Dis","doi-asserted-by":"publisher"},{"DOI":"10.1097/01.AOG.0000152351.13671.99","key":"noi260021r14","year":"2005","issue":"2","author":"Sibai","volume":"105","first-page":"402","unstructured":null,"article-title":"Diagnosis, prevention, and management of eclampsia.","journal-title":"Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1528-1157.44.s10.3.x","key":"noi260021r15","year":"2003","issue":"s10","author":"Bruns","volume":"44","first-page":"2","unstructured":null,"article-title":"The epidemiology of traumatic brain injury: a review.","journal-title":"Epilepsia","doi-asserted-by":"publisher"},{"DOI":"10.1001/archneur.59.2.195","key":"noi260021r16","year":"2002","issue":"2","author":"Silverman","volume":"59","first-page":"195","unstructured":null,"article-title":"Poststroke seizures.","journal-title":"Arch Neurol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.yebeh.2010.09.014","key":"noi260021r18","year":"2010","issue":"4","author":"Koby","volume":"19","first-page":"584","unstructured":null,"article-title":"Questioning the role of abuse in behavioral spells and epilepsy.","journal-title":"Epilepsy Behav","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2022.109305","key":"noi260021r19","year":"2022","issue":null,"author":"Woo","volume":"232","first-page":null,"unstructured":null,"article-title":"Alcohol consumption on unprovoked seizure and epilepsy: an updated meta-analysis.","journal-title":"Drug Alcohol Depend","doi-asserted-by":"publisher"},{"DOI":"10.2174/15733998113099990060","key":"noi260021r20","year":"2013","issue":"4","author":"Yun","volume":"9","first-page":"350","unstructured":null,"article-title":"Association between seizures and diabetes mellitus: a comprehensive review of literature.","journal-title":"Curr Diabetes Rev","doi-asserted-by":"publisher"},{"DOI":"10.5698/1535-7511-12.5.184","key":"noi260021r21","year":"2012","issue":"5","author":"Pandis","volume":"12","first-page":"184","unstructured":null,"article-title":"Seizures in Alzheimer disease: clinical and epidemiological data.","journal-title":"Epilepsy Curr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jns.2011.11.029","key":"noi260021r22","year":"2012","issue":"1-2","author":"Atkinson","volume":"315","first-page":"156","unstructured":null,"article-title":"Refractory status epilepticus secondary to CNS vasculitis, a role for epilepsy surgery.","journal-title":"J Neurol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1111/epi.14442","key":"noi260021r23","year":"2018","issue":"7","author":"Alkhachroum","volume":"59","first-page":"1392","unstructured":null,"article-title":"Risk of seizures and status epilepticus in older patients with liver disease.","journal-title":"Epilepsia","doi-asserted-by":"publisher"},{"DOI":"10.1212/WNL.0000000000011077","key":"noi260021r24","year":"2020","issue":"24","author":"Stefanidou","volume":"95","first-page":"e3241","unstructured":null,"article-title":"Bi-directional association between epilepsy and dementia: the Framingham Heart Study.","journal-title":"Neurology","doi-asserted-by":"publisher"},{"DOI":"10.1016/0021-9681(87)90171-8","key":"noi260021r25","year":"1987","issue":"5","author":"Charlson","volume":"40","first-page":"373","unstructured":null,"article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","journal-title":"J Chronic Dis","doi-asserted-by":"publisher"},{"DOI":null,"key":"noi260021r26","year":"1987","issue":"82","author":"Breslow","volume":null,"first-page":"1","unstructured":null,"article-title":"Statistical methods in cancer research. volume II–the design and analysis of cohort studies.","journal-title":"IARC Sci Publ","doi-asserted-by":null},{"DOI":"10.1002/ijc.28396","key":"noi260021r28","year":"2014","issue":"4","author":"Kaae","volume":"134","first-page":"932","unstructured":null,"article-title":"Epilepsy, anti-epileptic medication use and risk of cancer.","journal-title":"Int J Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.seizure.2012.05.014","key":"noi260021r29","year":"2012","issue":"7","author":"Kahlenberg","volume":"21","first-page":"540","unstructured":null,"article-title":"Seizure prognosis of patients with low-grade tumors.","journal-title":"Seizure","doi-asserted-by":"publisher"},{"DOI":"10.2217/cns.15.29","key":"noi260021r30","year":"2015","issue":"5","author":"Kerkhof","volume":"4","first-page":"347","unstructured":null,"article-title":"Seizures in oligodendroglial tumors.","journal-title":"CNS Oncol","doi-asserted-by":"publisher"},{"DOI":null,"key":"noi260021r31","year":"1986","issue":"1","author":"Shirts","volume":"77","first-page":"83","unstructured":null,"article-title":"Cancer incidence in a cohort of patients with seizure disorders.","journal-title":"J Natl Cancer Inst","doi-asserted-by":null},{"DOI":"10.1016/j.seizure.2016.05.015","key":"noi260021r32","year":"2017","issue":null,"author":"Crocker","volume":"49","first-page":"74","unstructured":null,"article-title":"Role of neuroimaging in first seizure diagnosis.","journal-title":"Seizure","doi-asserted-by":"publisher"},{"DOI":"10.3390/epidemiologia4020012","key":"noi260021r33","year":"2023","issue":"2","author":"Tancredi","volume":"4","first-page":"117","unstructured":null,"article-title":"Screening and surveillance bias in cancer.","journal-title":"Epidemiologia (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2004.12.149","key":"noi260021r36","year":"2004","issue":"14","author":"Barnholtz-Sloan","volume":"22","first-page":"2865","unstructured":null,"article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2010.01.025","key":"noi260021r37","year":"2010","issue":"6","author":"Grivennikov","volume":"140","first-page":"883","unstructured":null,"article-title":"Immunity, inflammation, and cancer.","journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1038/nrneurol.2010.178","key":"noi260021r38","year":"2011","issue":"1","author":"Vezzani","volume":"7","first-page":"31","unstructured":null,"article-title":"The role of inflammation in epilepsy.","journal-title":"Nat Rev Neurol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.neulet.2011.02.040","key":"noi260021r39","year":"2011","issue":"3","author":"Ravizza","volume":"497","first-page":"223","unstructured":null,"article-title":"Inflammation and prevention of epileptogenesis.","journal-title":"Neurosci Lett","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.metop.2024.100305","key":"noi260021r40","year":"2024","issue":null,"author":"Karamanolis","volume":"23","first-page":null,"unstructured":null,"article-title":"Paraneoplastic hypoglycemia: an overview for optimal clinical guidance.","journal-title":"Metabol Open","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.nbd.2007.03.002","key":"noi260021r41","year":"2007","issue":"3","author":"Abdelmalik","volume":"26","first-page":"646","unstructured":null,"article-title":"Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction.","journal-title":"Neurobiol Dis","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12979-017-0112-5","key":"noi260021r42","year":"2018","issue":"1","author":"Leonardi","volume":"15","first-page":"1","unstructured":null,"article-title":"Ageing: from inflammation to cancer.","journal-title":"Immun Ageing","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jns.2023.120584","key":"noi260021r43","year":"2023","issue":null,"author":"Aronica","volume":"446","first-page":null,"unstructured":null,"article-title":"Epilepsy and brain tumors: two sides of the same coin.","journal-title":"J Neurol Sci","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms22168661","key":"noi260021r44","year":"2021","issue":"16","author":"Nooreldeen","volume":"22","first-page":"8661","unstructured":null,"article-title":"Current and future development in lung cancer diagnosis.","journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41575-022-00612-y","key":"noi260021r45","year":"2022","issue":"8","author":"Shaukat","volume":"19","first-page":"521","unstructured":null,"article-title":"Current and future colorectal cancer screening strategies.","journal-title":"Nat Rev Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2024.5534","key":"noi260021r46","year":"2024","issue":"22","author":"Nicholson","volume":"331","first-page":"1918","unstructured":null,"article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.7326/M17-0868","key":"noi260021r47","year":"2017","issue":"6","author":"van Es","volume":"167","first-page":"410","unstructured":null,"article-title":"Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data.","journal-title":"Ann Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm9082389","key":"noi260021r48","year":"2020","issue":"8","author":"D’Astous","volume":"9","first-page":"2389","unstructured":null,"article-title":"Screening for occult cancer in patients with venous thromboembolism.","journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.seizure.2016.11.029","key":"noi260021r50","year":"2017","issue":null,"author":"Oto","volume":"44","first-page":"143","unstructured":null,"article-title":"The misdiagnosis of epilepsy: appraising risks and managing uncertainty.","journal-title":"Seizure","doi-asserted-by":"publisher"},{"DOI":null,"key":"noi260021r27","year":"1982","issue":null,"author":"Rothman","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"noi260021r1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Moore? A. Epilepsy vs. seizure: understanding a symptom vs. disease. Verywell Health. Accessed January 20, 2026. https://www.verywellhealth.com/epilepsy-vs-seizure-7966112","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"noi260021r3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Blaabjerg? M. Kramper. Sundhed.dk. Accessed January 20, 2026. https://www.sundhed.dk/sundhedsfaglig/laegehaandbogen/neurologi/symptomer-og-tegn/kramper/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"noi260021r17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Withdrawal seizure. ScienceDirect. Accessed May 9, 2025. https://www.sciencedirect.com/topics/medicine-and-dentistry/withdrawal-seizure","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"noi260021r34","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Fayed? L. Brain tumor symptoms: seizures, headaches, dizziness, and more. Verywell Health. Accessed January 19, 2026. https://www.verywellhealth.com/symptoms-of-brain-tumors-513565","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"noi260021r35","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Drappatz? J, Avila? EK. Seizures in patients with primary and metastatic brain tumors. UpToDate. Accessed January 20, 2026. https://www.uptodate.com/contents/seizures-in-patients-with-primary-and-metastatic-brain-tumors?utm_source=chatgpt.com","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"noi260021r49","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Lloyd? J, Brookes? A. One test to detect multiple cancers – where are we now? Cancer Research UK. Accessed January 20, 2026. https://news.cancerresearchuk.org/2024/06/12/multi-cancer-tests-mced-tests-where-are-we-now/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Neurology"],"reference-count":50,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,27]]},"references-count":50,"short-container-title":["JAMA Neurol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamaneurol.2026.0894","is_oa":true,"title":"Risk of Cancer in Patients With First-Time Seizure","updated":"2026-05-02T09:05:40+00:00","published_date":"2026-04-27","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13122496/","pmh_id":"oai:pubmedcentral.nih.gov:13122496","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13122496/"}}},"created_at":"2026-05-07T22:49:11.501Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"condition","value":"Brain Neoplasm","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"condition","value":"Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"condition","value":"Seizure","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"sample_size","value":"n=49,894","value_numeric":49894},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"study_design","value":"Population-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"warning","value":"Follow-up duration varied across patients; the 5–20 year absolute risk of 13.4% reflects cumulative incidence and includes background population aging effects.","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"warning","value":"Full text was not accessible; summary is based solely on the abstract and results section provided.","value_numeric":null},{"paper_doi":"10.1001/jamaneurol.2026.0894","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the scale and duration of elevated nonneurological cancer risk, which extends beyond what current first-seizure guidelines typically address — but guideline adoption remains to be seen.","value_numeric":null}],"summaries":{"what_studied":"This population-based cohort study examined cancer risk (neurological and nonneurological) in 49,894 adults with a first-time hospital-diagnosed seizure and no prior cancer history, using Danish national registries (1996–2022) with follow-up up to 20 years.","key_result":"Within the first year, absolute cancer risk was 4.1% (SIR 5.30; 95% CI, 5.07–5.54), driven largely by neurological cancers (AR 2.4%; SIR 76.1). Risk remained modestly elevated from 1–5 years (SIR 1.18) and 5–20 years (SIR 1.34). Nonneurological cancer risk was also elevated short-term (AR 1.7%; SIR 2.32) and long-term (AR 12.8%; SIR 1.33).","limitations":"- Registry-based design cannot confirm seizure etiology or rule out subclinical cancer at time of seizure diagnosis.\n- Nonmelanoma skin cancer was excluded, which may underestimate total cancer burden.\n- No adjustment for individual-level risk factors (e.g., smoking, alcohol) that could confound nonneurological cancer risk.","practice_takeaway":"A first-time seizure should prompt consideration of neuroimaging and broader cancer workup, especially within the first year — neurological cancer risk is 76-fold above baseline. Even beyond 1 year, a modestly elevated nonneurological cancer risk (SIR ~1.15–1.33) suggests ongoing vigilance in select patients."}},{"doi":"10.1001/jamapsychiatry.2026.0418","pmid":"42018336","title":"Dialectical Behavior Therapy vs Schema Therapy for Patients With Borderline Personality Disorder","journal_title":"JAMA Psychiatry","journal_issn":"2168-622X","published_at":"2026-04-22T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13103886/","source_score":51,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-08T13:23:37.864Z","updated_at":"2026-05-08T13:23:37.864Z","tags":[{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"condition","value":"Borderline Personality Disorder","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"modality","value":"Dialectical Behavior Therapy","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"modality","value":"Schema Therapy","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"sample_size","value":"n=204","value_numeric":204},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"warning","value":"Full text was not accessible; summary is based solely on the abstract and results section provided.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"warning","value":"Level of evidence assigned as 2 (well-designed RCT) rather than 1, as this is a single trial without meta-analytic pooling.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0418","tag_type":"warning","value":"The trial was designed as a superiority RCT, not an equivalence or non-inferiority trial — the absence of a significant difference does not formally establish equivalence between DBT and ST.","value_numeric":null}],"summaries":{"what_studied":"This 3-year multicenter RCT (BOOTS project, 9 Dutch outpatient centers, Jan 2019–Apr 2025) compared DBT vs schema therapy (ST) in 204 adults aged 18–65 with BPD, randomized to 2 years of combined group-individual treatment, with primary outcome of BPD severity change (BPDSI-5) measured through 1-year post-treatment follow-up.","key_result":"No significant difference between DBT and ST in reducing BPD severity (P = .27, Cohen d = 0.15; 95% CI, −0.17 to 0.47 on BPDSI-5 at 36 months); both treatments produced large improvements across all outcomes. Dropout was also similar (DBT: 52% at 2 years; ST: 46% at 2 years).","limitations":"- The trial was powered for superiority, not equivalence — so a true null result cannot be confirmed statistically.\n- High dropout rates (~46–52% by 2 years) may limit interpretation of long-term outcomes.\n- The sample was predominantly female (84.3%) and Dutch, limiting generalizability.","practice_takeaway":"For outpatients with BPD, DBT and schema therapy appear equally effective — clinicians can reasonably base treatment choice on patient preference, therapist expertise, or local availability. Future work should focus on identifying which patients do best with which approach."}}],"initialOffset":3,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"warning","value":"Full text was not accessible; summary is based solely on the abstract and results section provided."}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Study limitation"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"warning","hub_tag_value":"Full text was not accessible; summary is based solely on the abstract and results section provided."}}}]] 25:null 29:[["$","title","0",{"children":"Study limitation: Full text was not accessible; summary is based solely on the abstract and results section provided | ReachRx"}],["$","meta","1",{"name":"description","content":"JAMA Neurology, Aug 2026 · 560 patients. “Full text was not accessible; summary is based solely on the abstract and results section provided.” Read the key result, limitations and practice takeaway."}],["$","link","2",{"rel":"canonical","href":"https://www.reachrx.ai/hub/tag/warning/Full%20text%20was%20not%20accessible%3B%20summary%20is%20based%20solely%20on%20the%20abstract%20and%20results%20section%20provided."}],["$","meta","3",{"property":"og:title","content":"Study limitation: Full text was not accessible; summary is based solely on the abstract and results section provided | ReachRx"}],["$","meta","4",{"property":"og:description","content":"JAMA Neurology, Aug 2026 · 560 patients. “Full text was not accessible; summary is based solely on the abstract and results section provided.” Read the key result, limitations and practice takeaway."}],["$","meta","5",{"property":"og:url","content":"https://www.reachrx.ai/hub/tag/warning/Full%20text%20was%20not%20accessible%3B%20summary%20is%20based%20solely%20on%20the%20abstract%20and%20results%20section%20provided."}],["$","meta","6",{"property":"og:type","content":"website"}],["$","meta","7",{"name":"twitter:card","content":"summary"}],["$","meta","8",{"name":"twitter:title","content":"Study limitation: Full text was not accessible; summary is based solely on the abstract and results section provided | ReachRx"}],["$","meta","9",{"name":"twitter:description","content":"JAMA Neurology, Aug 2026 · 560 patients. “Full text was not accessible; summary is based solely on the abstract and results section provided.” Read the key result, limitations and practice takeaway."}]]

Papers

Papers